ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Magnesium Sulfate to Prevent Brain Injury in Premature Infants

This study is ongoing, but not recruiting participants.

Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier: NCT00065949
  Purpose

Premature infants are at risk for acute brain injuries and long-term developmental problems such as cerebral palsy (CP). Research suggests that high levels of magnesium at and around the time of birth may decrease the risk of brain injuries. This study will evaluate the effects of giving magnesium to premature infants.


Condition Intervention Phase
Brain Injuries
Cerebral Palsy
Drug: magnesium sulfate
Phase III

MedlinePlus related topics:   Cerebral Palsy    Paralysis    Premature Babies    Traumatic Brain Injury   

Drug Information available for:   Magnesium    Magnesium sulfate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   Magnesium Prevention of Brain Injury in Preterm Infants

Further study details as provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):

Study Start Date:   August 1987
Estimated Study Completion Date:   February 2003

Detailed Description:

Premature infants weighing less than 1500 grams (3.3 lbs) represent approximately 1.3% of liveborn infants, yet comprise at least 25% of all children who are subsequently diagnosed with CP. Antepartum exposure to magnesium (Mg) may prevent or ameliorate early brain injury (intracranial hemorrhage and cystic periventricular leukomalacia), as well as long-term adverse neurodevelopmental outcomes (CP and mental retardation) in very low birthweight (VLBW) preterm infants. In preliminary studies, short- and long-term neuroprotection were associated with initial serum Mg levels above 3.0 mEq/L. This study will determine whether early abnormal neurosonographic findings and long-term adverse neurodevelopmental outcomes in VLBW premature infants are influenced by different levels of serum Mg achieved during the first week of life.

Infants will be randomized to either "standard" Mg therapy or "high" Mg therapy. Standard Mg therapy consists of no supplemental Mg for the first 3 days of life followed by intravenous magnesium sulfate (MgSO4) aimed at attaining serum Mg levels in the normal range of 1.2-2.3 mEq/L. High Mg therapy consists of using intravenous MgSO4 to maintain higher (nonharmful) serum Mg levels between 3.5-5.5 mEq/L for the first 3 days of life and between 2.5-3.5 mEq/L for the next 4 days. The high Mg infants will subsequently have their serum Mg levels maintained at 2.4+0.3 mEq/L using oral magnesium gluconate for the remainder of their neonatal hospitalization.

Infants will be evaluated for early brain injury with head ultrasound studies 12 to 24 hours after birth, at 2 to 3 day intervals while ventilator support is required, and at weekly intervals until discharge. The infants will subsequently be assessed in the high-risk follow-up clinic for a minimum of 24 months (corrected for degree of prematurity). At 24 months of age, they will be evaluated by a pediatric neurologist for the presence of cerebral palsy. They will be tested serially for problems in early cognition (mental, language, and perceptual ability), as well as fine and gross motor skills.

  Eligibility
Ages Eligible for Study:   up to 12 Hours
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria

  • Born at 23 to 32 weeks’ gestation
  • Weighs 500 to 1500 grams (1.1 to 3.3 lbs)
  • Requires mechanical ventilation
  • Less than 12 hours of age at time of enrollment

Exclusion Criteria

  • Multiple congenital anomalies
  • Single congenital anomaly of the central nervous system
  • Unlikely to be available for duration of the study
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00065949

Locations
United States, Pennsylvania
Thomas Jefferson University    
      Philadelphia, Pennsylvania, United States, 19107

Sponsors and Collaborators

Investigators
Principal Investigator:     Thomas E. Wiswell, M.D.     Thomas Jefferson University    
  More Information


Publications:

Study ID Numbers:   HD21453, NICHD-13, NICHD-0523, 5 RO1 HD21453
First Received:   August 1, 2003
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00065949
Health Authority:   United States: Federal Government

Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
Low birthweight infants  
Magnesium supplementation  
Intracranial hemorrhage  
Cystic periventricular leukomalacia  
Mental retardation  

Study placed in the following topic categories:
Birth Weight
Craniocerebral Trauma
Magnesium Sulfate
Brain Damage, Chronic
Wounds and Injuries
Disorders of Environmental Origin
Central Nervous System Diseases
Trauma, Nervous System
Intracranial Hemorrhages
Hemorrhage
Brain Diseases
Leukomalacia, Periventricular
Mental Retardation
Paralysis
Cerebral Palsy
Leukomalacia
Brain Injuries

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Nervous System Diseases
Physiological Effects of Drugs
Calcium Channel Blockers
Anesthetics
Central Nervous System Depressants
Reproductive Control Agents
Cardiovascular Agents
Pharmacologic Actions
Membrane Transport Modulators
Tocolytic Agents
Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers